These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1999851)

  • 1. Clinical and pharmacologic study of orally administered uridine.
    van Groeningen CJ; Peters GJ; Nadal JC; Laurensse E; Pinedo HM
    J Natl Cancer Inst; 1991 Mar; 83(6):437-41. PubMed ID: 1999851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
    Kelsen DP; Martin D; O'Neil J; Schwartz G; Saltz L; Sung MT; von Borstel R; Bertino J
    J Clin Oncol; 1997 Apr; 15(4):1511-7. PubMed ID: 9193347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
    Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
    Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
    van Groeningen CJ; Leyva A; Kraal I; Peters GJ; Pinedo HM
    Cancer Treat Rep; 1986 Jun; 70(6):745-50. PubMed ID: 3731137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of fluorouracil toxicity with uridine.
    van Groeningen CJ; Peters GJ; Pinedo HM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):148-54. PubMed ID: 1557641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
    Vanhoefer U; Harstrick A; Köhne CH; Achterrath W; Rustum YM; Seeber S; Wilke H
    J Clin Oncol; 1999 Mar; 17(3):907-13. PubMed ID: 10071283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
    Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
    Jefford M; Michael M; Rosenthal MA; Davis ID; Green M; McClure B; Smith J; Waite B; Zalcberg J
    Invest New Drugs; 2004 Apr; 22(2):185-92. PubMed ID: 14739668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
    van Groeningen CJ; Peters GJ; Leyva A; Laurensse E; Pinedo HM
    J Natl Cancer Inst; 1989 Jan; 81(2):157-62. PubMed ID: 2909757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
    Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
    Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine.
    van Groeningen CJ; Peters GJ; Pinedo HM
    Ann Oncol; 1993 Apr; 4(4):317-20. PubMed ID: 8518223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
    Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
    J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
    Pizzorno G; Yee L; Burtness BA; Marsh JC; Darnowski JW; Chu MY; Chu SH; Chu E; Leffert JJ; Handschumacher RE; Calabresi P
    Clin Cancer Res; 1998 May; 4(5):1165-75. PubMed ID: 9607574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
    Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
    J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.